Dr. Jane Winter, MD
Hematology & Oncology (Hematology & Oncology Physician)
675 N Saint Clair St, Galter 21-100
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 383
Licensed in Illinois since 1978, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036057716 (first issued 1978; active) -
Hematology (Internal Medicine) Physician
IL license 036057716 (first issued 1978; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Delnor Community Hospital Geneva, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 383
- Services billed
- 50,792
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,830 | 30 |
| Injection, fosaprepitant, 1 mg | 4,950 | 29 |
| Injection, pembrolizumab, 1 mg | 4,400 | 15 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,920 | 34 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,601 | 16 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1,248 | 16 |
| Injection, bortezomib, 0.1 mg | 1,221 | 25 |
| Injection, pemetrexed, not otherwise specified, 10 mg | 1,193 | 11 |
| Injection, atropine sulfate, 0.01 mg | 800 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 712 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Chicago, IL | 87 |
| Allopurinol Other prescribers in Chicago, IL | 29 |
| Calquence (acalabrutinib maleate) | 18 |
| Brukinsa (zanubrutinib) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $5,507 in total to this clinician.
| Genentech USA, Inc. | $5,463 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $24.89 |
| Sobi, Inc | $19.17 |
| Consulting Fee | $5,330 |
|---|---|
| Food and Beverage | $177 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $2,460 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,760,495 in research payments for these studies, mostly to the institutions running them.
- A Phase II multi-center open-label trial of six doses of pembrolizumab monotherapy prior to limited chemotherapy as front-line therapy for patients with classical Hodgkin lymphoma, including elderly patients
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.